medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2021, Número S3

<< Anterior Siguiente >>

Cardiovasc Metab Sci 2021; 32 (S3)


Epidemiología y carga de morbilidad y mortalidad en dislipidemias y aterosclerosis

Borrayo-Sánchez G

Idioma: Inglés [English version]
Referencias bibliográficas: 21
Paginas: s143-146
Archivo PDF: 259.27 Kb.





REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kuijpers PMJC. History in medicine: the story of cholesterol, lipids and cardiology. E-Journal-of-Cardiology-Practice [On Line]. 2021 [Available in: https://www.escardio.org]; 19: 9.

  2. World Health Organization. Mortality and global health estimates. The top 10 causes of death. 2019. Available in: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

  3. Goff Jr DC, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY et al. Dyslipidemia prevalence, treatment, and control in the multi-ethnic study of atherosclerosis (MESA). Gender, ethnicity, and coronary artery calcium. Circulation. 2006; 113: 647-656.

  4. Xing L, Jing L, Tian Y, Yan H, Zhang B, Sun Q et al. Epidemiology of dyslipidemia and associated cardiovascular risk factors in northeast China: a cross-sectional study. Nutr Metab Cardiovasc Dis. 2020; 30: 2262-2270.

  5. Joffres M, Shileds M, Trembal MS, Gorber SC. Dyslipidemia prevalence, treatment, control, and awareness in the Canadian Health Measures Survey. Can J Public Health. 2013; 104: e252-e257.

  6. Blacher J, Gabet A, Vallée A, Ferrières J, Bruckert E, Farnier M et al. Prevalence and management of hypercholesterolemia in France, the Esteban observational study. Medicine (Baltimore). 2020; 99: e23445.

  7. NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020; 582: 73-77.

  8. Hernández-Alcaraz C, Aguilar-Salinas CA, Mendoza-Herrera K, Pedroza-Tobías A, Villalpando S, Shamah-Levy T et al. Dyslipidemia prevalence, awareness, treatment and control in Mexico: results of the Ensanut 2012. Salud Publica Mex. 2020; 62: 137-146.

  9. Meaney A, Ceballos-Reyes G, Gutiérrez-Salmeán G, Samaniego-Méndez V, Vela-Huerta A, Alcocer L et al. Cardiovascular risk factors in a Mexican middle-class urban population. The Lindavista Study. Baseline data. Arch Cardiol Mex. 2013; 83: 249-256.

  10. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM et al. Global burden of cardiovascular diseases and risk factors, 1990-2019. Update from the GBD 2019 Study. J Am Cardiol Coll. 2020; 76: 2982-3021.

  11. Lanas F, Avezum A, Bautista L, Diaz R, Luna M, Islam S et al. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation. 2007; 115: 1067-1074.

  12. Canto JG, Kiefe CI, Rogers WJ, Peterson ED, Frederick PD, French WJ et al. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA. 2011; 306: 2120-2127.

  13. Kopin L, Lowenstein C. Dyslipidemia. Ann Intern Med. 2017; 167: ITC81-ITC96.

  14. Estrada García T, Meaney A, López-Hernández D, Meaney E, Sánchez-Hernández O, Rodríguez-Arellano E et al. Hypertension and lipid triad are the most important attributable risks for myocardial infarction in a middle class urban Mexican population. Nutr & Metabol. 2013; 63: 1343.

  15. Rivas-Gomez B, Almeda-Valdés P, Tussié-Luna M, Aguilar-Salinas C. Dyslipidemia in Mexico, a call for action. Rev Invest Clin. 2018; 70: 211-216.

  16. Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; 41: 111-188.

  17. Estruch R, Ruilope L, Cosentino F. The year in cardiovascular medicine 2020: epidemiology and prevention. Eur Heart J. 2021; 42: 813-821.

  18. Orsó E, Schmitz G. Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clin Res Cardiol Suppl. 2017; 2 (Suppl 1): 31-37.

  19. Patel AP, Wang M, Pirruccello JP, Ellinor PT, NG K, Kathiresan S et al. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease. New insights from a large national Biobank. Arterioscler Thromb Vasc Biol. 2021; 41: 465-474.

  20. Costello B, Silverman E, Doukky R, Braun L, Aggarwal N, Deng Y et al. Lipoprotein (a) and increased cardiovascular risk in women. Clin Cardiol. 2016; 39: 96-102.

  21. Wu MF, Xu KZ, Guo YG, Yu J, Wu Y, Lin LM. Lipoprotein(a) and atherosclerotic cardiovascular disease: current understanding and future perspectives. Cardiovasc Drugs Ther. 2019; 33: 739-748.




2020     |     www.medigraphic.com